Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy

Fig. 1

Leronlimab binds CCR5 in human breast cancer cells. a In order to determine the binding of leronlimab to human CCR5 in breast cancer cells, we used an MDA-MB-231 human breast cancer cell line transfected with a human CCR5 expression vector as a model system (MDA-MB-231-CCR5 cells). A commercial APC conjugated mouse anti-human/mouse/rat CCR5 antibody from R&D (FAB1802A) (APC-αCCR5), was used as a positive control to assess CCR5 positive cells. MDA-MB-231-CCR5 cells were stained with both APC-αCCR5 and leronlimab using the concentration from 1 to 140 mg/ml. Alexa Fluor 488-conjugated mouse anti-human IgG was used as a secondary antibody to measure leronlimab binding cells. Analysis of leronlimab binding with CCR5 by FACS is shown in a. Leronlimab binding with human CCR5 was validated. b The efficiency of leronlimab binding to CCR5-positive cells was up to 98% compared with CCR5 antibody (FAB1802A)

Back to article page
\